<?xml version='1.0' encoding='utf-8'?>
<document id="25681130"><sentence text="Guanfu base A, an antiarrhythmic alkaloid of Aconitum coreanum, Is a CYP2D6 inhibitor of human, monkey, and dog isoforms."><entity charOffset="33-41" id="DDI-PubMed.25681130.s1.e0" text="alkaloid" /></sentence><sentence text="Guanfu base A (GFA) is a novel heterocyclic antiarrhythmic drug isolated from Aconitum coreanum (Lèvl"><entity charOffset="31-43" id="DDI-PubMed.25681130.s2.e0" text="heterocyclic" /></sentence><sentence text=") rapaics and is currently in a phase IV clinical trial in China" /><sentence text=" However, no study has investigated the influence of GFA on cytochrome P450 (P450) drug metabolism" /><sentence text=" We characterized the potency and specificity of GFA CYP2D inhibition based on dextromethorphan O-demethylation, a CYP2D6 probe substrate of activity in human, mouse, rat, dog, and monkey liver microsomes"><entity charOffset="79-95" id="DDI-PubMed.25681130.s5.e0" text="dextromethorphan" /></sentence><sentence text=" In addition, (+)-bufuralol 1'-hydroxylation was used as a CYP2D6 probe for the recombinant form (rCYP2D6), 2D1 (rCYP2D1), and 2D2 (rCYP2D2) activities" /><sentence text=" Results show that GFA is a potent noncompetitive inhibitor of CYP2D6, with inhibition constant Ki = 1" /><sentence text="20 ± 0" /><sentence text="33 μM in human liver microsomes (HLMs) and Ki = 0" /><sentence text="37 ± 0" /><sentence text="16 μM for the human recombinant form (rCYP2D6)" /><sentence text=" GFA is also a potent competitive inhibitor of CYP2D in monkey (Ki = 0" /><sentence text="38 ± 0" /><sentence text="12 μM) and dog (Ki = 2" /><sentence text="4 ± 1" /><sentence text="3 μM) microsomes" /><sentence text=" However, GFA has no inhibitory activity on mouse or rat CYP2Ds" /><sentence text=" GFA did not exhibit any inhibition activity on human recombinant CYP1A2, 2A6, 2C8, 2C19, 3A4, or 3A5, but showed slight inhibition of 2B6 and 2E1" /><sentence text=" Preincubation of HLMs and rCYP2D6 resulted in the inactivation of the enzyme, which was attenuated by GFA or quinidine"><entity charOffset="110-119" id="DDI-PubMed.25681130.s19.e0" text="quinidine" /></sentence><sentence text=" Beagle dogs treated intravenously with dextromethorphan (2 mg/ml) after pretreatment with GFA injection showed reduced CYP2D metabolic activity, with the Cmax of dextrorphan being one-third that of the saline-treated group and area under the plasma concentration-time curve half that of the saline-treated group"><entity charOffset="40-56" id="DDI-PubMed.25681130.s20.e0" text="dextromethorphan" /><entity charOffset="91-94" id="DDI-PubMed.25681130.s20.e1" text="GFA" /><entity charOffset="163-174" id="DDI-PubMed.25681130.s20.e2" text="dextrorphan" /><pair ddi="false" e1="DDI-PubMed.25681130.s20.e0" e2="DDI-PubMed.25681130.s20.e0" /><pair ddi="false" e1="DDI-PubMed.25681130.s20.e0" e2="DDI-PubMed.25681130.s20.e1" /><pair ddi="false" e1="DDI-PubMed.25681130.s20.e0" e2="DDI-PubMed.25681130.s20.e2" /><pair ddi="false" e1="DDI-PubMed.25681130.s20.e1" e2="DDI-PubMed.25681130.s20.e1" /><pair ddi="false" e1="DDI-PubMed.25681130.s20.e1" e2="DDI-PubMed.25681130.s20.e2" /></sentence><sentence text=" This study suggests that GFA is a specific CYP2D6 inhibitor that might play a role in CYP2D6 medicated drug-drug interaction"><entity charOffset="26-36" id="DDI-PubMed.25681130.s21.e0" text="GFA" /></sentence><sentence text=" " /></document>